Welcome to our dedicated page for Kewaunee Scienti SEC filings (Ticker: KEQU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Kewaunee Scientific Corporation’s (NASDAQ: KEQU) SEC filings, allowing investors and researchers to review the company’s official regulatory disclosures. Kewaunee files reports and current event disclosures with the U.S. Securities and Exchange Commission as a public company listed on The Nasdaq Global Market.
In these filings, users can find quarterly and annual financial information, including discussions of segment performance for the domestic, international, and corporate segments. The company also explains its use of non-GAAP measures such as EBITDA, Segment EBITDA, Adjusted EBITDA, adjusted net earnings, and adjusted net earnings per share, and provides reconciliations to the most comparable GAAP measures.
Kewaunee’s Form 8-K current reports cover topics such as quarterly and annual results, amendments to bylaws, board appointments, annual meeting outcomes, and the timing of earnings releases. Proxy materials, such as the company’s definitive proxy statement, describe matters submitted to shareholders, including director elections, auditor ratification, advisory votes on executive compensation, and the frequency of such advisory votes.
Filings also document capital markets and governance actions, including details of share repurchase program approvals or amendments, loan agreements and related disclosures, and information about non-employee director compensation and committee assignments. Together, these documents provide a structured view of Kewaunee’s financial condition, governance framework, and significant corporate events.
On Stock Titan, KEQU filings are updated in step with new submissions to the SEC’s EDGAR system. AI-powered summaries highlight key points from long-form documents, helping users quickly understand the main changes, financial metrics, and governance decisions without reading every page of each filing.
Kewaunee Scientific Corp (KEQU) reported a Form 4 filing disclosing equity transactions for Douglas J. Batdorff, VP of Manufacturing Operations. On June 25, 2025, Batdorff was granted 4,528 Restricted Stock Units (RSUs) under the FY26 program.
The RSU grant is structured in two components:
- 50% Service-Based RSUs: Vesting in three equal annual installments starting June 30, 2026, contingent on continued employment
- 50% Performance-Based RSUs: Vesting subject to achieving performance goals over a three-year period
Each RSU represents the right to receive one share of Kewaunee Scientific common stock. The grant was made at $0 cost to the executive. The ultimate number of shares received will depend on continued employment and performance metrics over the three-year period.
On 25 June 2025, Kewaunee Scientific Corp. (ticker KEQU) filed a Form 4 reporting that its Vice President – Sales & Marketing (Americas), Ryan S. Noble, received an equity award of 4,380 restricted stock units (RSUs) coded “A” (acquired from the issuer at no cost). Each RSU represents the contingent right to receive one common share.
The award is split 50/50 between (a) service-based RSUs that vest in three equal annual installments beginning 30 June 2026, and (b) performance-based RSUs that vest only if three-year performance goals are achieved. No cash value or exercise price is attached; the grant price is listed as $0.
After the transaction, Noble directly beneficially owns 4,380 derivative securities; no changes to non-derivative share ownership were disclosed. The filing, signed by attorney-in-fact Donald T. Gardner III on 27 June 2025, reports no sales, disposals, or additional acquisitions beyond this RSU grant.
The disclosure signals routine executive compensation rather than an open-market purchase or sale, and does not contain earnings data or other corporate developments.
Kewaunee Scientific (NASDAQ: KEQU) filed a Form 4 disclosing that Vice President-Information Technology Mandar Ranade was granted 4,392 restricted stock units (RSUs) on 25 June 2025.
The award converts to an equal number of common shares at a $0 exercise price. 50 % of the RSUs are service-based, vesting in three equal annual installments beginning 30 June 2026, while the remaining 50 % are performance-based and vest only if three-year performance goals are achieved. Following the grant, the reporting person beneficially owns 4,392 derivative securities. No shares were sold or otherwise disposed of.
Elizabeth D. Phillips, VP of Human Resources at Kewaunee Scientific Corp (KEQU), received a grant of 4,111 Restricted Stock Units (RSUs) on June 25, 2025. The RSU grant is structured in two parts:
- 50% Service-Based RSUs: 2,055.5 units vesting in three equal annual installments starting June 30, 2026, contingent on continued employment
- 50% Performance-Based RSUs: 2,055.5 units subject to three-year performance goals
The RSUs represent the right to receive an equivalent number of common stock shares upon vesting. The grant was made at $0 cost to the executive. Final vesting of performance-based units will depend on achievement of undisclosed performance metrics over the three-year period. This equity award aligns executive compensation with both long-term service and company performance goals.
Kewaunee Scientific (Nasdaq: KEQU) filed a Form 8-K on June 25 2025 to furnish Item 2.02 – Results of Operations and Financial Condition. The company released its fourth-quarter and fiscal-year results for the period ended April 30 2025 via a press release, attached as Exhibit 99.1.
The information is expressly treated as "furnished," not "filed," thereby avoiding Section 18 liability and limiting incorporation into future SEC documents unless specifically cited. No other reportable events were disclosed.